METHOD FOR PREDICTION OF CLINICAL COURSE OF YERSINIOSIS IN CHILDREN Russian patent published in 2011 - IPC G01N33/49 G01N33/52 

FIELD: medicine.

SUBSTANCE: initial (3 to 12 day) assessment of clinical symptoms of disease (fever and exanthema) is combined with measuring blood serum C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and specific antibodies (AT) and if observing: - fever response for less than 2 days, exanthema duration for less than 1.5 days, the CRP value less than 7.5 mg/l, ESR less than 15 mm/hour; the IFN-γ level less than 75 pg/ml, circulating immune complex 0.115 optical density units and lower, and specific antibody production more than 8.32 log2, a chronic clinical course of yersiniosis is predicted; - fever response for more than 12 days, exanthema duration for more than 3 days, the CRP value more than 15 mg/l, ESR more than 30 mm/hour; the IFN-γ level more than 150 pg/ml, circulating immune complex 0.130 optical density units and higher, specific antibody production less than 7.32 log₂, a severe yersiniosis with associating organ lesions is predicted; - fever response for more than 12 days, exanthema duration for more than 9 days, the CRP value more than 5 mg/l, ESR more than 50 mm/hour; the IFN-γ level less than 150 pg/ml, circulating immune complex 0.250 optical density units and higher, and specific antibody production more than 9.32 log₂, clinical outcome of yersiniosis in a systemic disease is predicted.

EFFECT: prevention of a chronic and prolonged clinical course of the disease.

3 tbl, 3 ex